FDMT (4D Molecular Therapeutics) Market Cap: $607.45 Mil (As of Jun. 25, 2026)


FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $11.62
GF Value $214.38
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Market Cap?

4D Molecular Therapeutics FDMT +0.30% 55 Market Cap is $607.45 Mil as of Jun. 25, 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $214.38 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,431 Biotechnology companies, 4D Molecular Therapeutics ranks better than 74.21% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). 4D Molecular Therapeutics's share price for the quarter that ended in Mar. 2026 was $9.31. 4D Molecular Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 52.27 Mil. Therefore, 4D Molecular Therapeutics's market cap for the quarter that ended in Mar. 2026 was $486.65 Mil.

4D Molecular Therapeutics's quarterly market cap increased from Sep. 2025 ($406.44 Mil) to Dec. 2025 ($432.06 Mil) and increased from Dec. 2025 ($432.06 Mil) to Mar. 2026 ($486.65 Mil).

4D Molecular Therapeutics's annual market cap declined from Dec. 2023 ($872.70 Mil) to Dec. 2024 ($255.07 Mil) but then increased from Dec. 2024 ($255.07 Mil) to Dec. 2025 ($432.06 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. 4D Molecular Therapeutics's Enterprise Value for Today is $237.09 Mil.


4D Molecular Therapeutics  (NAS:FDMT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


4D Molecular Therapeutics Market Cap Related Terms


4D Molecular Therapeutics Market Cap Historical Data

* Premium members only.

The historical data trend for 4D Molecular Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics Market Cap Chart

4D Molecular Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only 707.02 724.65 872.70 255.07 432.06

4D Molecular Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 149.63 173.26 406.44 432.06 486.65

FDMT vs KYTX, XOMA, OVID: Market Cap Comparison

For the Biotechnology subindustry, 4D Molecular Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4D Molecular Therapeutics Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Market Cap falls into.


FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4D Molecular Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

4D Molecular Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=$7.5*57.608
=$432.06

4D Molecular Therapeutics's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=$9.31*52.272
=$486.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $607.45 Mil mean?
4D Molecular Therapeutics (FDMT) has a Market Cap of $607.45 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on 4D Molecular Therapeutics and its competitors. According to the industry distribution chart, 4D Molecular Therapeutics ranks #369 out of 1431 companies in the Biotechnology industry, placing it in the top 25.8%.
Is 4D Molecular Therapeutics' Market Cap too high?
4D Molecular Therapeutics' current Market Cap is $607.45 Mil. The Biotechnology industry median Market Cap is 117.63. 4D Molecular Therapeutics' value of $607.45 Mil is 416.4% above this industry median. Based on the distribution chart, 4D Molecular Therapeutics ranks #369 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Market Cap compare to KYTX and XOMA?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #369 out of 1431 companies for Market Cap. This puts 4D Molecular Therapeutics in the upper half of its industry. The industry median Market Cap is 117.63. 4D Molecular Therapeutics' value of $607.45 Mil is 416.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4D Molecular Therapeutics's current Market Cap of $607.45 Mil is 416.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on 4D Molecular Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4D Molecular Therapeutics's current Market Cap is $607.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $214.38, compared to a current price of $11.62 — trading 94.6% below its estimated fair value. The current Market Cap is $607.45 Mil and 416.4% above the Biotechnology industry median of 117.63. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Market Cap is $607.45 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $11.62 is trading 94.6% below its estimated GF Value™ of $214.38. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Market Cap: $607.45 Mil
  • GF Value™: $214.38 vs. price of $11.62 (94.6% below fair value)
  • GF Score™: 55/100 with 7 warning signs
  • Industry Position: 416.4% above the Biotechnology median (#369 of 1431)

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.62
Price
$214.38
GF Value